BioCentury
ARTICLE | Clinical News

AZD5363: Phase I started

April 18, 2011 7:00 AM UTC

AstraZeneca began an open-label, European Phase I trial to evaluate ascending-doses of oral AZD5363 in about 84 patients. AstraZeneca has worldwide rights to the compound from Astex (see BioCentury Au...